FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia
Tóm tắt
Từ khóa
Tài liệu tham khảo
Heron, National Vital Statistics Reports
DeFrances, National Health Statistics Reports
Jencks, 2009, Rehospitalizations among patients in the Medicare fee-for-service program, N Engl J Med, 360, 1418, 10.1056/NEJMsa0803563
Lim, 2009, BTS guidelines for the management of community acquired pneumonia in adults: update 2009, Thorax, 64, iii1, 10.1136/thx.2009.121434
Mandell, 2007, Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults, Clin Infect Dis, 44, S27, 10.1086/511159
Ge, 2008, In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States, Antimicrob Agents Chemother, 52, 3398, 10.1128/AAC.00149-08
Iizawa, 2004, In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599, J Infect Chemother, 10, 146, 10.1007/s10156-004-0309-3
Sader, 2005, Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains, Antimicrob Agents Chemother, 49, 3501, 10.1128/AAC.49.8.3501-3512.2005
Fine, 1997, A prediction rule to identify low-risk patients with community-acquired pneumonia, N Engl J Med, 336, 243, 10.1056/NEJM199701233360402
File, 2010, Integrated analysis of FOCUS 1 and FOCUS 2: randomized, double-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia, Clin Infect Dis, 51, 1395, 10.1086/657313
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use
Niederman, 2005, American Thoracic Society and the Infectious Diseases Society of America guidelines for management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia, Am J Respir Crit Care Med, 171, 388, 10.1164/rccm.200405-644ST
Clinical and Laboratory Standards Institute, 2006, Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically—Seventh Edition: Approved Standard M7-A7
Clinical and Laboratory Standards Institute, 2008, Performance Standards for Antimicrobial Susceptibility Testing—Eighteenth Informational Supplement M100-S18
Farrington, 1990, Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk, Stat Med, 9, 1447, 10.1002/sim.4780091208
Niederman, 2001, Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention, Am Respir Crit Care Med, 163, 1730, 10.1164/ajrccm.163.7.at1010
FDA, Guidance for Industry. Community-Acquired Bacterial Pneumonia: Developing Drugs for Treatment
Kosowska-Shick, 2010, Affinity of ceftaroline and other β-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae, Antimicrob Agents Chemother, 54, 1670, 10.1128/AAC.00019-10
Moisan, 2010, Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae, J Antimicrob Chemother, 65, 713, 10.1093/jac/dkp503
Tanaseanu, 2008, Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia, Diagn Microbiol Infect Dis, 61, 329, 10.1016/j.diagmicrobio.2008.04.009
Ortiz-Ruiz, 2004, Ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults: combined analysis of two multicentre randomized, double-blind studies, J Antimicrob Chemother, 53, ii59
Pertel, 2008, Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia, Clin Infect Dis, 46, 1142, 10.1086/533441
Tygacil® (Tigecycline) for Intravenous Use: Prescribing Information
Corey, 2010, CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections, J Antimicrob Chemother, 65, iv41
Corey, 2010, Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin structure infection, Clin Infect Dis, 51, 641, 10.1086/655827
Wilcox, 2010, CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections, J Antimicrob Chemother, 65, iv53
Maxipime® (Cefepime Hydrochloride, USP) for Injection: Prescribing Information